Denali Therapeutics Inc [DNLI] stock is trading at $15.68, up 1.23%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DNLI shares have gain 23.08% over the last week, with a monthly amount glided 13.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on April 10, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight. On February 11, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $31 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $31 on January 07, 2025. William Blair initiated its recommendation with a Outperform. Stifel upgraded its rating to Buy for this stock on December 16, 2024, but kept the price target unchanged to $37.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $10.57 and $33.33 over the past year. Currently, Wall Street analysts expect the stock to reach $38.5 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $15.68 at the most recent close of the market. An investor can expect a potential return of 145.54% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.31 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.19 points at the first support level, and at 14.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.00, and for the 2nd resistance point, it is at 16.31.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 8.46. Also, the Quick Ratio is 8.46, while the Cash Ratio stands at 1.71.
Transactions by insiders
Recent insider trading involved Ho Carole, Chief Medical Officer, that happened on Jan 06 ’25 when 12255.0 shares were sold. Chief Medical Officer, Ho Carole completed a deal on Jan 07 ’25 to sell 2907.0 shares. Meanwhile, COFO and Secretary Schuth Alexander O. sold 12255.0 shares on Jan 06 ’25.
